Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
life sciences
national blog main
san francisco blog main
9
×
boston blog main
boston top stories
biotech
national top stories
new york blog main
new york top stories
san francisco top stories
startups
deals
san diego blog main
san diego top stories
cancer
clinical trials
eli lilly
fda
raleigh-durham blog main
raleigh-durham top stories
vc
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
indiana blog main
indiana top stories
ipo
national
novartis
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accent therapeutics
acetylon pharmaceuticals
What
medicines
9
×
new
9
×
biotech
cancer
companies
drug
bio
community
deal
developing
diagnostics
disease
fda
ipo
research
startup
therapeutics
vaccines
activity
adds
aim
aiming
aims
alliance
ambys
amgen
approach
approval
approvals
areas
based
bets
better
big
biogen
biosciences
bio’s
black
boost
brii
Language
unset
Current search:
medicines
×
photo
×
new
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines